| Literature DB >> 34122544 |
Yingchao Chen1, Bing Han1, Jie Yu1, Yi Chen1, Jing Cheng1, Chunfang Zhu1, Fangzhen Xia1, Ningjian Wang1, Yingli Lu1.
Abstract
BACKGROUND: The prevalence of autoimmune thyroid diseases (AITDs), especially Hashimoto's thyroiditis (HT), has increased dramatically in China. Moreover, China is experiencing the largest scale of urbanization in the world. We intended to explore the relationship between rapid urbanization and HT.Entities:
Year: 2021 PMID: 34122544 PMCID: PMC8189768 DOI: 10.1155/2021/9967712
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Flowchart of this study.
Comparison of TSH, TPOAb, and TGAb concentrations in two locations.
| TPOAb | TGAb | TSH | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SY | NJ |
| SY | NJ |
| SY | NJ |
| |
| Overall | 14.00 (14.00–14.00) | 34.60 (28.00–44.58) | <0.001 | 7.50 (7.50–15.00) | 21.05 (15.00–29.62) | <0.001 | 2.38 ± 1.46 | 3.13 ± 5.55 | <0.001 |
|
| |||||||||
|
| |||||||||
| <40 | 14.00 (14.00–14.00) | 38.60 (30.30–47.00) | <0.001 | 7.50 (7.50–7.50) | 22.50 (16.43–35.13) | <0.001 | 2.15 ± 1.14 | 2.55 ± 1.56 | 0.004 |
| 40–50 | 14.00 (14.00–14.00) | 36.20 (29.00–43.15) | <0.001 | 7.50 (7.50–16.25) | 21.90 (16.98–31.60) | <0.001 | 2.42 ± 1.61 | 3.55 ± 10.67 | 0.053 |
| 50–60 | 14.00 (14.00–14.00) | 35.35 (28.00–45.45) | <0.001 | 7.50 (7.50–7.50) | 20.90 (15.00–27.65) | <0.001 | 2.39 ± 1.36 | 3.11 ± 5.21 | 0.009 |
| 60–70 | 14.00 (14.00–14.00) | 31.40 (7.75–43.33) | <0.001 | 7.50 (7.50–7.50) | 20.30 (15.00–29.67) | <0.001 | 2.56 ± 1.70 | 3.10 ± 2.39 | <0.001 |
| ≥70 | 14.00 (14.00–14.00) | 28.30 (7.64–41.00) | <0.001 | 7.50 (7.50–16.00) | 19.50 (15.00–28.10) | <0.001 | 2.12 ± 1.01 | 3.18 ± 2.30 | <0.001 |
|
| |||||||||
|
| |||||||||
| Male | 14.00 (14.00–14.00) | 33.45 (28.00–43.80) | <0.001 | 7.50 (7.50–7.50) | 20.05 (15.00–25.11) | <0.001 | 2.15 ± 1.29 | 2.43 ± 1.88 | 0.003 |
| Female | 14.00 (14.00–14.00) | 34.85 (28.00–45.00) | <0.001 | 7.50 (7.50–17.00) | 22.15 (15.00–39.34) | <0.001 | 2.56 ± 1.57 | 3.46 ± 6.58 | <0.001 |
Logistic regression analysis for risk factors of TPOAb positivity.
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| Rapid urbanization | 1.564 (1.221, 2.004) | 1.584 (1.233, 2.035) | 1.473 (1.128, 1.923) |
| Sex | 2.503 (1.865, 3.358) | 2.432 (1.666, 3.548) | 2.492 (1.699, 3.655) |
| Age | 0.998 (0.989, 1.008) | 0.997 (0.987, 1.007) | 0.997 (0.987, 1.007) |
| Smoke | 1.032 (0.653, 1.632) | 0.999 (0.630, 1.585) | |
| BMI | 1.030 (0.992, 1.069) | ||
| Diabetes | 0.857 (0.586, 1.255) |
Logistic regression analysis for risk factors for TGAb positivity.
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| Rapid urbanization | 1.805 (1.432, 2.275) | 1.826 (1.445, 2.306) | 1.689 (1.319, 2.164) |
| Sex | 3.951 (2.917, 5.352) | 4.005 (2.783, 5.763) | 3.980 (2.760, 5.738) |
| Age | 0.997 (0.988, 1.005) | 0.995 (0.987, 1.004) | 0.994 (0.985, 1.004) |
| Smoke | 0.908 (0.606, 1.360) | 0.907 (0.603, 1.363) | |
| BMI | 1.032 (0.996, 1.068) | ||
| Diabetes | 0.801 (0.559, 1.147) |
Genetic risk estimation for 4 SNPs and TPOAb.
| SNP | Genotypes | SY frequencies | OR (95%) | NJ frequencies | OR (95%) | ||
|---|---|---|---|---|---|---|---|
| TPOAb‒ | TPOAb+ | TPOAb‒ | TPOAb+ | ||||
| SNP1 (rs9277555) | AA | 236 (27.5) | 14 (17.9) | 1 (ref) | 297 (25.9) | 41 (24.3) | 1 (ref) |
| AG | 432 (50.4) | 49 (62.8) | 1.912 (1.034, 3.536) | 568 (49.6) | 85 (50.3) | 1.084 (0.728, 1.614) | |
| GG | 189 (22.1) | 15 (19.2) | 1.338 (0.630, 2.841) | 280 (24.5) | 43 (25.4) | 1.112 (0.704, 1.759) | |
| SNP2 (rs11675434) | CC | 427 (48.6) | 34 (42.5) | 1 (ref) | 547 (47.9) | 68 (40.2) | 1 (ref) |
| CT | 384 (43.7) | 30 (37.5) | 0.981 (0.589, 1.634) | 481 (42.1) | 75 (44.4) | 1.254 (0.884, 1.780) | |
| TT | 68 (7.7) | 16 (20.0) | 2.955 (1.547, 5.643) | 115 (10.1) | 26 (15.4) | 1.819 (1.109, 2.982) | |
| SNP3 (rs301799) | TT | 585 (66.3) | 49 (62.8) | 1 (ref) | 820 (71.4) | 110 (65.1) | 1 (ref) |
| CT | 278 (31.5) | 27 (34.6) | 1.160 (0.710, 1.895) | 292 (25.4) | 47 (27.8) | 1.200 (0.832, 1.731) | |
| CC | 20 (2.3) | 2 (2.6) | 1.194 (0.271, 5.258) | 36 (3.1) | 12 (7.1) | 2.485 (1.255, 4.919) | |
| SNP4 (rs3094228) | AA | 600 (69.6) | 50 (66.7) | 1 (ref) | 832 (72.8) | 129 (76.3) | 1 (ref) |
| AG | 244 (28.3) | 24 (32.0) | 1.180 (0.710, 1.964) | 282 (24.7) | 37 (21.9) | 0.846 (0.573, 1.249) | |
| GG | 18 (2.1) | 1 (1.3) | 0.667 (0.087, 5.098) | 29 (2.5) | 3 (1.8) | 0.667 (0.200, 2.222) | |
GMDR analysis for the best interaction combination models.
| Locus no. | Best combination | Cross-validation consistency | Testing accuracy |
|
|---|---|---|---|---|
| Gene-gene interactions | ||||
| 1 | SNP2 | 10/10 | 0.5264 | 0.0547 |
| 2 | SNP2 × SNP3 | 10/10 | 0.5314 | 0.0547 |
| 3 | SNP1 × SNP2 × SNP3 | 10/10 | 0.5466 | 0.0547 |
|
| ||||
| Gene-urbanization interactions | ||||
| 1 | Urbanization | 10/10 | 0.5610 | 0.0547 |
| 2 | SNP2 × urbanization | 10/10 | 0.5688 | 0.001 |
| 3 | SNP2 × SNP3 × urbanization | 10/10 | 0.5725 | 0.001 |